FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. News release. FDA. September 2, 2022. Accessed September 2, 2022. https://bit.ly/3TOU798 Oh D, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplain in advanced biliary tract cancer...
531 Background: At the primary analysis of TOPAZ-1 (NCT03875235; data cut-off [DCO] Aug 11, 2021), durvalumab (D) + gemcitabine and cisplatin (GC) significantly improved overall survival (OS) vs placebo (PBO) + GC in participants (pts) with advanced biliary tract cancer (BTC), with ...
Gemcitabine, cisplatin, durvalumab, and tremelimumab (an anti-CTLA4 antibody) in advanced, unresectable biliary tract cancer had an objective response rate of 70% in a phase II study (2). Given this response to immunotherapy plus chemotherapy, the 4-drug combination of gemcitabine, cisplatin, ...